Semaglutide and pancreatic cancer risk

A meta-analysis published on 15 June 2026 in Diabetes, Obesity & Metabolism examined whether semaglutide is associated with an increased risk of pancreatic cancer across randomised controlled trials^[1]. The study, led by Cho-Han Chiang and colleagues, follows the same group's broader 2025 review of GLP-1 receptor agonists and cancer in the Annals of Internal Medicine, which found no increased risk across 48 trials and 94,245 participants^[2].

What the evidence shows so far

The pancreatic-cancer question has followed GLP-1 receptor agonists since the early days of the class. Concerns first surfaced from adverse-event reports in the 2010s, and early pharmacovigilance signals prompted both the FDA and the EMA to request additional safety data from manufacturers. Since then, a string of meta-analyses has pooled the available RCT data, and the direction of the evidence has been consistent: no statistically significant increase in pancreatic cancer risk.

In 2025, a meta-analysis by Wen and colleagues pooled 62 RCTs covering 66,232 patients and reported an overall risk ratio of 1.30 (95% CI: 0.86 to 1.97, p = 0.22) for pancreatic cancer with GLP-1 receptor agonist use, a result that did not reach statistical significance^[3]. A further meta-analysis by Wali and colleagues, published in Frontiers in Pharmacology in February 2026, pooled 93 RCTs and reported a hazard ratio of 0.78 (95% CI: 0.61 to 0.95) for pancreatic cancer across the GLP-1 receptor agonist class, suggesting a possible protective signal rather than harm^[4].

Chiang's earlier Annals of Internal Medicine review rated the certainty of evidence for pancreatic cancer and GLP-1 receptor agonists as moderate, concluding that these drugs "probably have little or no effect" on pancreatic cancer risk. The new semaglutide-focused analysis in Diabetes, Obesity & Metabolism narrows the lens to the single most widely prescribed molecule in the class. Semaglutide accounted for roughly 42% of the trials in the 2025 Annals review, making it the dominant molecule in the pooled dataset even before this dedicated analysis.

Pancreatitis is a separate question

Pancreatic cancer risk should not be confused with pancreatitis risk. The semaglutide prescribing information (Ozempic, US label) carries a warning for acute pancreatitis, including fatal and non-fatal haemorrhagic or necrotising cases. In the clinical trial programme, acute pancreatitis occurred at a rate of 0.3 per 100 patient-years on semaglutide versus 0.2 per 100 patient-years in comparator groups^[5]. Pancreatitis is an acute inflammatory event: it causes rapid-onset abdominal pain, and in most cases it resolves with treatment. Pancreatic cancer is a malignancy with a different aetiology, different risk factors and a very different prognosis. Readers encountering headlines about "pancreatic risks" with semaglutide should note which condition is being discussed, because the clinical implications are not interchangeable.

What we still do not know

Three limitations run through all of these meta-analyses. First, median follow-up in GLP-1 receptor agonist trials is typically under two years. Cancer latency often exceeds five years, so the window may be too short to detect a real signal in either direction. Second, none of the pooled trials was designed with pancreatic cancer as a primary endpoint; the events are captured as adverse-event reports, not confirmed diagnoses adjudicated by an oncology panel. Third, the number of pancreatic cancer events across all pooled trials remains small, which means the confidence intervals are wide enough to accommodate both a modest increase and a modest decrease in risk.

Chiang and colleagues noted in 2025 that long-term randomised or observational studies with at least five years of follow-up and prespecified cancer endpoints are needed before the question can be considered settled.

Where this leaves patients and clinicians

For people currently prescribed semaglutide for type-2 diabetes or chronic weight management, the available trial evidence does not support an increased pancreatic cancer risk. That is the consistent finding across three independent meta-analyses published between 2025 and 2026. It is not, however, a guarantee of safety at the ten-year or twenty-year mark, because the data to answer that question do not yet exist.

Ongoing observational registries, including the Nordic registry study (NCT04572165) tracking semaglutide users with type-2 diabetes, may eventually provide the longer follow-up window these meta-analyses lack. Until those results arrive, the current evidence base offers reassurance but not a final answer.

Patients with concerns should discuss them with a prescribing clinician rather than adjusting treatment on the basis of a single meta-analysis. For background on semaglutide's regulatory status and clinical profile, see the semaglutide overview on this site.